OCUP · Ocuphire Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.16M | - | $3.08M | $2.88M | $4.37M | - | $3.87M | $1.11M | $1.71M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.58M | - | $6.41M | $6.02M | $7.95M | - | $8.98M | $6.09M | $4.75M | - |
| SG&A | $5.94M | - | $4.98M | $5.77M | $6.35M | - | $2.89M | $3.35M | $4.67M | - |
| Total Operating Expenses | $16.52M | - | $11.39M | $11.79M | $14.30M | - | $11.88M | $9.44M | $9.42M | - |
| D&A | $13.0K | - | - | - | $13.0K | - | $0 | $0 | $0 | - |
| Operating Income | ($14.36M) | - | ($8.31M) | ($8.91M) | ($9.93M) | - | ($8.01M) | ($8.33M) | ($7.71M) | - |
| Interest Expense | $69.0K | - | $0 | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($65.53M) | - | ($17.45M) | ($7.42M) | ($8.19M) | - | ($7.53M) | ($7.76M) | ($7.11M) | - |
| EPS - Basic | ($0.75) | - | ($0.25) | ($0.12) | ($0.24) | - | ($0.29) | ($0.30) | ($0.29) | - |
| EPS - Diluted | ($0.75) | - | ($0.25) | ($0.12) | ($0.24) | - | ($0.29) | ($0.30) | ($0.29) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $59.96M | $45.09M | $30.82M | $32.43M | $41.79M | $30.32M | $36.63M | $41.41M | $47.16M | $50.50M |
| Accounts Receivable | $1.73M | $2.00M | $2.92M | $3.40M | $3.08M | $3.56M | $1.86M | $1.36M | $1.92M | $926.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.42M | $3.29M | $2.40M | $1.47M | $2.43M | $3.15M | $844.0K | $634.0K | $2.06M | $2.15M |
| Current Assets | $66.60M | $50.04M | $35.91M | $38.44M | $47.93M | $36.61M | $40.39M | $44.83M | $51.84M | $53.95M |
| Total Assets | $66.79M | $50.24M | $36.12M | $38.66M | $48.17M | $36.86M | $40.39M | $44.83M | $51.84M | $53.95M |
| Current Liabilities | $9.34M | $7.78M | $29.09M | $20.19M | $24.25M | $11.29M | $6.09M | $4.20M | $5.79M | $4.04M |
| Long-term Debt | $1.20M | $1.13M | $1.07M | $0 | - | - | - | - | - | - |
| Total Liabilities | $87.89M | $34.90M | $30.16M | $21.19M | $24.25M | $11.29M | $6.09M | $4.20M | $5.79M | $4.04M |
| Stockholders' Equity | ($45.84M) | $15.35M | $5.97M | $17.47M | $5.07M | $6.72M | $34.30M | $40.64M | $46.06M | $49.91M |
| Retained Earnings | ($254.12M) | ($188.59M) | ($172.07M) | ($154.61M) | ($147.19M) | ($139.00M) | ($103.86M) | ($96.34M) | ($88.57M) | ($81.47M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.73M) | - | - | - | ($8.99M) | - | - | - | ($5.72M) | - |
| Investing Cash Flow | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Financing Cash Flow | $27.59M | - | - | - | $20.46M | - | - | - | $2.38M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -665.9% | - | -269.9% | -309.0% | -227.2% | - | -207.1% | -748.9% | -450.5% | - |
| EBITDA margin | -665.3% | - | - | - | -226.9% | - | -207.1% | -748.9% | -450.5% | - |
| Net margin | -3038.2% | - | -566.9% | -257.5% | -187.5% | - | -194.6% | -698.3% | -415.3% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 490.4% | - | 208.2% | 209.0% | 182.0% | - | 232.3% | 547.3% | 277.6% | - |
| SG&A / Revenue | 275.6% | - | 161.8% | 200.1% | 145.2% | - | 74.8% | 301.6% | 272.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -98.1% | - | -48.3% | -19.2% | -17.0% | - | -18.6% | -17.3% | -13.7% | - |
| Return on equity | 143.0% | - | -292.5% | -42.5% | -161.5% | - | -21.9% | -19.1% | -15.4% | - |
| Return on invested capital | - | - | -93.3% | -40.3% | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.13 | 6.43 | 1.23 | 1.90 | 1.98 | 3.24 | 6.63 | 10.68 | 8.96 | 13.35 |
| Quick ratio | 7.13 | 6.43 | 1.23 | 1.90 | 1.98 | 3.24 | 6.63 | 10.68 | 8.96 | 13.35 |
| Cash ratio | 6.42 | 5.80 | 1.06 | 1.61 | 1.72 | 2.68 | 6.02 | 9.86 | 8.15 | 12.49 |
| Leverage | ||||||||||
| Debt / Equity | -0.03 | 0.07 | 0.18 | 0.00 | - | - | - | - | - | - |
| Debt / Assets | 0.02 | 0.02 | 0.03 | 0.00 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -208.2x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.46 | 3.27 | 6.05 | 2.21 | 9.49 | 5.48 | 1.18 | 1.10 | 1.13 | 1.08 |
| Liabilities / Assets | 1.32 | 0.69 | 0.83 | 0.55 | 0.50 | 0.31 | 0.15 | 0.09 | 0.11 | 0.07 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.09 | 0.07 | 0.09 | - | 0.10 | 0.02 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 293d | - | 346d | 430d | 257d | - | 175d | 446d | 410d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -50.6% | - | -20.4% | 159.2% | 155.4% | - | -67.6% | -69.7% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | 99.2% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | 30.6% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -44.7% | - | -3.8% | -6.9% | -28.8% | - | - | -54.5% | -25.7% | - |
| Net income growth (YoY) | -699.8% | - | -131.9% | 4.4% | -15.3% | - | - | -56.5% | -22.7% | - |
| EPS growth (YoY) | -212.5% | - | 13.8% | 60.0% | 17.2% | - | - | -25.0% | -3.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 128.3% | -82.6% | -57.0% | -89.0% | -86.5% | -31.8% | 7.8% | 11.7% | 7.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Ocuphire Pharma against the 5 most active filers in the same SIC group.